SYNAREL Izrael - engleski - Ministry of Health

synarel

pfizer pfe pharmaceuticals israel ltd - nafarelin acetate - nasal solution - nafarelin acetate 2 mg/ml - nafarelin - nafarelin - - controlled ovarian stimulation programmes prior to in-vitro fertilisation.- hormonal management of endometriosis, including pain relief and reduction of endometrial lesions. - uterine fibroids.

CEVIMELINE HYDROCHLORIDE capsule Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

cevimeline hydrochloride capsule

bryant ranch prepack - cevimeline hydrochloride (unii: p81q6v85np) (cevimeline - unii:k9v0cdq56e) - cevimeline is indicated for the treatment of symptoms of dry mouth in patients with sjögren’s syndrome. cevimeline is contraindicated in patients with uncontrolled asthma, known hypersensitivity to cevimeline, and when miosis is undesirable, e.g., in acute iritis and in narrow-angle (angle-closure) glaucoma.

CEVIMELINE HYDROCHLORIDE capsule Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

cevimeline hydrochloride capsule

bryant ranch prepack - cevimeline hydrochloride (unii: p81q6v85np) (cevimeline - unii:k9v0cdq56e) - cevimeline hydrochloride is indicated for the treatment of symptoms of dry mouth in patients with sjögren’s syndrome. cevimeline hydrochloride is contraindicated in patients with uncontrolled asthma, known hypersensitivity to cevimeline, and when miosis is undesirable, e.g., in acute iritis and in narrow-angle (angle-closure) glaucoma.

CEVIMELINE HYDROCHLORIDE capsule Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

cevimeline hydrochloride capsule

bryant ranch prepack - cevimeline hydrochloride (unii: p81q6v85np) (cevimeline - unii:k9v0cdq56e) - cevimeline is indicated for the treatment of symptoms of dry mouth in patients with sjögren’s syndrome. cevimeline is contraindicated in patients with uncontrolled asthma, known hypersensitivity to cevimeline, and when miosis is undesirable, e.g., in acute iritis and in narrow-angle (angle-closure) glaucoma.

HUMULIN I 100 IU/ML Suspension for Injection Irska - engleski - HPRA (Health Products Regulatory Authority)

humulin i 100 iu/ml suspension for injection

eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulin (human) - humulin - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

HUMULIN I KWIKPEN 100 IU/ML Suspension for Injection Irska - engleski - HPRA (Health Products Regulatory Authority)

humulin i kwikpen 100 iu/ml suspension for injection

eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulin (human) - humulin i - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

HUMULIN S 100 IU/ML Solution for Injection Irska - engleski - HPRA (Health Products Regulatory Authority)

humulin s 100 iu/ml solution for injection

eli lilly and company limited - human insulin (recombinant dna origin) - solution for injection - 100 iu/ml - insulins and analogues for injection, fast-acting - humulin s - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

ZYDELIG- idelalisib tablet, film coated Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

zydelig- idelalisib tablet, film coated

gilead sciences, inc. - idelalisib (unii: yg57i8t5m0) (idelalisib - unii:yg57i8t5m0) - idelalisib 100 mg - zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (cll) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. limitations of use zydelig is not indicated and is not recommended for first-line treatment of any patient, including patients with cll, small lymphocytic lymphoma (sll), follicular lymphoma (fl), and other indolent non-hodgkin lymphomas. zydelig is not indicated and is not recommended in combination with bendamustine and rituximab, or in combination with rituximab for the treatment of patients with fl, sll, and other indolent non-hodgkin lymphomas. zydelig is contraindicated in patients with a history of serious hypersensitivity reactions to idelalisib, including anaphylaxis, or patients with a history of toxic epidermal necrolysis with any drug [see warnings and precautions (5.6, 5.7)] . risk summary based on findings in animal studies and the mechanism of action [see clinical pharmac

SYNAREL NASAL SPRAY nafarelin (as acetate) 2mg/mL Australija - engleski - Department of Health (Therapeutic Goods Administration)

synarel nasal spray nafarelin (as acetate) 2mg/ml

pfizer australia pty ltd - nafarelin, quantity: 2 mg/ml - spray, solution - excipient ingredients: benzalkonium chloride; sorbitol; glacial acetic acid; hydrochloric acid; purified water; sodium hydroxide - indications as at 31 august 1995. synarel is indicated for the hormonal management of visually proven endometriosis, including pain relief and reduction of endometriotic lesions and for use in controlled ovarian stimulation programmes prior to in-vitro fertilisation, under the supervision of an infertility specialist.

Alimta Europska Unija - engleski - EMA (European Medicines Agency)

alimta

eli lilly nederland b.v. - pemetrexed - mesothelioma; carcinoma, non-small-cell lung - antineoplastic agents - malignant pleural mesotheliomaalimta in combination with cisplatin is indicated for the treatment of chemotherapy-naïve patients with unresectable malignant pleural mesothelioma.non-small-cell lung canceralimta in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology.alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.alimta is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology.